Jeph Herrin

Jeph Herrin

Auto-generated profile, based on publicly available information

Jeph Herrin

Yale School of Medicine

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2014 in Health Services Research
Verified
Journal Article
Closed access
PDF file
JHJeph Herrin
Jeph Herrin
JAJustin St. Andre
Justin St. Andre
KKKevin Kenward
Kevin Kenward
MJMaulik S. Joshi
Maulik S. Joshi
AAAnne‐Marie J. Audet
Anne‐Marie J. Audet
SHStephen C. Hines
Stephen C. Hines

1 May 2012 in Annals of Internal Medicine
Verified
Journal Article
Closed access
EBElizabeth H. Bradley
Elizabeth H. Bradley
LCLeslie A. Curry
Leslie A. Curry
ESErica S. Spatz
Erica S. Spatz
JHJeph Herrin
Jeph Herrin
ECEmily J. Cherlin
Emily J. Cherlin
HKHarlan M. Krumholz
Harlan M. Krumholz
Mortality after acute myocardial infarction (AMI) varies greatly between U.S. hospitals, even accounting for patient factors. This cross-sectional survey of 537 U.S. hospitals identified several ho... Background: Despite recent improvements in survival after acute myocardial infarction (AMI), U.S. hospitals vary 2-fold in their 30-day risk-standardized mortality rates (RSMRs). Nevertheless, info...

3 May 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
JHJeph Herrin
Jeph Herrin
NANeena S. Abraham
Neena S. Abraham
XYXiaoxi Yao
Xiaoxi Yao
PNPeter A. Noseworthy
Peter A. Noseworthy
JIJonathan Inselman
Jonathan Inselman
CNChe Ngufor
Che Ngufor
Physicians have long used prediction models to stratify patients according to their risk of adverse outcomes. Such risk stratification can promote better treatment decisions, more efficient use of monitoring, and better implementation of approaches to mitigate risk.1 One outcome for which risk stratification is routinely used is related to the decision to prescribe antithrombotic medications (vitamin K antagonists, direct oral anticoagulants [DOACs], and/or thienopyridine antiplatelet agents) to patients with cardiovascular diseases. One of the key goals of this risk stratification is to incorporate the risk of gastrointestinal bleeding (GIB) in the context of the treatment decision. Given the severity of GIB2,3 and the widespread use of antithrombotic agents in this population, several risk models have been developed to predict bleeding, including HAS-BLED (hypertension, abnormal kidney and liver function, stroke, bleeding, labile international normalized ratio, older age, and drug or alcohol use), ATRIA (anticoagulation and risk factors in atrial fibrillation), ORBIT (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), and HEMORR(2)HAGES (hepatic or kidney disease, ethanol abuse, malignancy, older age, reduced platelet count or function, rebleeding, hypertension, anemia, genetic factors, excessive fall risk, and stroke).4-7

25 June 2014 in Trials
Verified
Journal Article
Open access
PDF file
EHErik P Hess
Erik P Hess
KWKirk D Wyatt
Kirk D Wyatt
AKAnupam B Kharbanda
Anupam B Kharbanda
JLJeffrey Louie
Jeffrey Louie
PDPeter S Dayan
Peter S Dayan
NKNathan Kuppermann
Nathan Kuppermann
Blunt head trauma is a common cause of death and disability in children worldwide. Cranial computed tomography (CT), the reference standard for the diagnosis of traumatic brain injury (TBI), exposes children to ionizing radiation which has been linked to the development of brain tumors, leukemia, and other cancers. We describe the methods used to develop and test the effectiveness of a decision aid to facilitate shared decision-making with parents regarding whether to obtain a head CT scan or to further observe their child at home. This is a protocol for a multicenter clinician-level parallel randomized trial to compare an intervention group receiving a decision aid, ‘Head CT Choice’, to a control group receiving usual care. The trial will be conducted at five diverse emergency departments (EDs) in Minnesota and California. Clinicians will be randomized to decision aid or usual care. Parents visiting the ED with children who are less than 18-years-old, have experienced blunt head trauma within 24 hours, and have one or two risk factors for clinically-important TBI (ciTBI) from the Pediatric Emergency Care Applied Research Network head injury clinical prediction rules will be eligible for enrollment. We will measure the effect of Head CT Choice on: (1) parent knowledge regarding their child’s risk of ciTBI, the available diagnostic options, and the risks of radiation exposure associated with a cranial CT scan (primary outcome); (2) parent engagement in the decision-making process; (3) the degree of conflict parents experience related to feeling uninformed; (4) patient and clinician satisfaction with the decision made; (5) the rate of ciTBI at seven days; (6) the proportion of patients in whom a cranial CT scan is obtained; and (7) seven-day healthcare utilization. To capture these outcomes, we will administer parent and clinician surveys immediately after each clinical encounter, obtain video recordings of parent-clinician discussions, administer parent healthcare utilization diaries, analyze hospital billing records, review the electronic medical record, and conduct telephone follow-up. This multicenter trial will robustly assess the effectiveness of a decision aid on patient-centered outcomes, safety, and healthcare utilization in parents of children with minor head trauma in five diverse EDs. ClinicalTrials.gov registration number: NCT02063087 . Registration date February 13, 2014.

1 January 2022 in Hypertension
Verified
Journal Article
Open access
PDF file
YLYuan Lu
Yuan Lu
YLYuntian Liu
Yuntian Liu
LDLovedeep Singh Dhingra
Lovedeep Singh Dhingra
DMDaisy Massey
Daisy Massey
CCCésar Caraballo
César Caraballo
HKHarlan M. Krumholz
Harlan M. Krumholz
Poor hypertension awareness and underuse of guideline-recommended medications are critical factors contributing to poor hypertension control. Using data from 8095 hypertensive people aged ≥18 years from the National Health and Nutrition Examination Survey (2011–2018), we examined recent trends in racial and ethnic differences in awareness and antihypertensive medication use, and their association with racial and ethnic differences in hypertension control. Between 2011 and 2018, age-adjusted hypertension awareness declined for Black, Hispanic, and White individuals, but the 3 outcomes increased or did not change for Asian individuals. Compared with White individuals, Black individuals had a similar awareness (odds ratio, 1.20 [0.96–1.45]) and overall treatment rates (1.04 [0.84–1.25]), and received more intensive antihypertensive medication if treated (1.41 [1.27–1.56]), but had a lower control rate (0.72 [0.61–0.83]). Asian and Hispanic individuals had significantly lower awareness rates (0.69 [0.52–0.85] and 0.74 [0.59–0.89]), overall treatment rates (0.72 [0.57–0.88] and 0.69 [0.55–0.82]), received less intensive medication if treated (0.60 [0.50–0.72] and 0.86 [0.75–0.96]), and had lower control rates (0.66 [0.54–0.79] and 0.69 [0.57–0.81]). The racial and ethnic differences in awareness, treatment, and control persisted over the study period and were consistent across age, sex, and income strata. Lower awareness and treatment were significantly associated with lower control in Asian and Hispanic individuals ( P <0.01 for all) but not in Black individuals. These findings highlight the need for interventions to improve awareness and treatment among Asian and Hispanic individuals, and more investigation into the downstream factors that may contribute to the poor hypertension control among Black individuals.

1 October 2019 in Social Science & Medicine
Verified
Journal Article
Closed access
NWNatalie M. Wittlin
Natalie M. Wittlin
JDJohn F. Dovidio
John F. Dovidio
SBSara E. Burke
Sara E. Burke
JPJulia M. Przedworski
Julia M. Przedworski
JHJeph Herrin
Jeph Herrin
MRMichelle van Ryn
Michelle van Ryn